Cargando…

Do We Need Anti-Prionic Compounds to Treat Alzheimer’s Disease?

Background: While phase III clinical trials for the treatment of Alzheimer’s disease (AD) keep failing regardless of the target, more and more data suggest that the toxic protein assemblies of amyloid-beta protein (Aβ) and tubulin binding protein (TAU) behave like prions. Irrespective of the questio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willbold, Dieter, Kutzsche, Janine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637388/ https://www.ncbi.nlm.nih.gov/pubmed/31208037 http://dx.doi.org/10.3390/molecules24122237

Ejemplares similares

TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer’s Disease Patients
por: Cuevas, Eva P., et al.
Publicado: (2022)

Could α-Synuclein Amyloid-Like Aggregates Trigger a Prionic Neuronal Invasion?
por: Busquets, Maria Antònia, et al.
Publicado: (2015)

In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease
por: Schemmert, Sarah, et al.
Publicado: (2021)

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
por: Kutzsche, Janine, et al.
Publicado: (2017)

Oral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival
por: Wintz, Katharina, et al.
Publicado: (2023)

A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
por: Post, Julia, et al.
Publicado: (2021)

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study
por: Kutzsche, Janine, et al.
Publicado: (2020)

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
por: Schartmann, Elena, et al.
Publicado: (2018)

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
por: Schemmert, Sarah, et al.
Publicado: (2018)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo
por: Kass, Bettina, et al.
Publicado: (2022)

Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease
por: Jiang, Nan, et al.
Publicado: (2015)

Peptides for Therapy and Diagnosis of Alzheimer’s Disease
por: Funke, Susanne Aileen, et al.
Publicado: (2012)

Can We Treat Neuroinflammation in Alzheimer’s Disease?
por: Sánchez-Sarasúa, Sandra, et al.
Publicado: (2020)

Evolutionary ecology of Chagas disease; what do we know and what do we need?
por: Flores‐Ferrer, Alheli, et al.
Publicado: (2017)

Should we treat pyrexia? And how do we do it?
por: Doyle, James F., et al.
Publicado: (2016)

Vitamin D deficiency in children with epilepsy: Do we need to detect and treat it?
por: Harijan, Pooja, et al.
Publicado: (2013)

Do we need elastography for EUS?
por: Dietrich, Christoph F., et al.
Publicado: (2020)

Compound heterozygosity for hemoglobin S and D: what do we need to know?()
por: Bonini-Domingos, Claudia Regina
Publicado: (2016)

AMP-Activated Protein Kinase: Do We Need Activators or Inhibitors to Treat or Prevent Cancer?
por: Russell, Fiona M., et al.
Publicado: (2020)

Dairy Fats and Cardiovascular Disease: Do We Really Need to Be Concerned?
por: Lordan, Ronan, et al.
Publicado: (2018)

40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?
por: Majewska, Anna, et al.
Publicado: (2022)

Why nutraceuticals do not prevent or treat Alzheimer's disease
por: Fisher, Anna EO, et al.
Publicado: (2005)

Do we need contrast agents for EUS?
por: Saftoiu, Adrian, et al.
Publicado: (2020)

Marine-Derived Compounds with Anti-Alzheimer’s Disease Activities
por: Hafez Ghoran, Salar, et al.
Publicado: (2021)

Sex-Related Motor Deficits in the Tau-P301L Mouse Model
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
por: Hasenoehrl, Carina, et al.
Publicado: (2017)

Women and COPD: do we need more evidence?
por: Gut-Gobert, Christophe, et al.
Publicado: (2019)

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
por: Ottenhoff, Tom H. M., et al.
Publicado: (2012)

How to treat diminutive polyps? Do we need more evidence?
por: East, James E.
Publicado: (2015)

Vitamin E and Alzheimer’s disease: what do we know so far?
por: Browne, Declan, et al.
Publicado: (2019)

Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease
por: Kutzsche, Janine, et al.
Publicado: (2023)

Why Do We Need Alternative Methods for Fungal Disease Management in Plants?
por: McLaughlin, Michael S., et al.
Publicado: (2023)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1(G93A) Transgenic Mice
por: Post, Julia, et al.
Publicado: (2021)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?
por: Youdim, Moussa B. H.
Publicado: (2010)

Alzheimer’s Disease – Why We Need Early Diagnosis
por: Rasmussen, Jill, et al.
Publicado: (2019)

Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)

Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?
por: Shapter, Frances Marie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f8o37ak370usq87mme7vme7k5r